Arrowhead Pharma Teams With Silicon Valley VC Vivo on New China Venture

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Arrowhead Pharma Teams With Silicon Valley VC Vivo on New China Venture

Pasadena-based Arrowhead Pharmaceuticals has landed a $60 million investment from Silicon Valley health care venture firm Vivo Capital to launch a new joint venture tapping into one of the fastest-growing markets for drugs: China.

On Monday, the local pharma firm announced that it is partnering with Vivo to form Visirna Therapeutics, a new venture that aims to develop and sell four of Arrowhead’s early-stage treatments in mainland China, Hong Kong, Macau and Taiwan. Arrowhead’s therapies utilize RNA interference—a new way to manipulate genes in cells that has largely been used to treat cardiometabolic diseases like hypertension, hyperlipidemia and type 2 diabetes.


Vivo—which has also backed health care startups like cancer-focused Genetron and surgical instrument company Golden Stapler—said it will leverage its network in China to recruit for leadership roles, parse through the country’s regulatory policies and develop commercialization strategies for the region.

“Greater China is an important region for global pharmaceutical products broadly, and specifically for medicines that treat cardiovascular and metabolic diseases,” Christopher Anzalone, Arrowhead’s president and CEO, said in a statement. He added that having a dedicated company in China that is entrenched in the country’s regulatory environment will allow Arrowhead to develop and commercialize drugs in the region faster, without taking away from its core business strategies.

Venture capital activity at large in China totaled $113.8 billion in 2021, according to PitchBook data—the second-highest annual figure on record, eclipsed only by the $126.5 billion invested in 2018. Nearly 19% of venture deals in China last year involved investors from outside the country, while dollars invested in China’s biotech and pharma sector soared nearly 44% from the year prior, according to Pitchbook.

American pharma companies like Merck and Eli Lilly have flocked to China as the country has looked to grow its health care sector to meet the rising demands of its aging population.

Subscribe to our newsletter to catch every headline.

Cadence

Riot Games Doubles Down on Mobile With ‘Aim Lab’ Investment

Samson Amore

Samson Amore is a reporter for dot.LA. He previously covered technology and entertainment for TheWrap and reported on the SoCal startup scene for the Los Angeles Business Journal. Samson is also a proud member of the Transgender Journalists Association. Send tips or pitches to samsonamore@dot.la and find him on Twitter at @Samsonamore. Pronouns: he/him

Riot Games Doubles Down on Mobile With ‘Aim Lab’ Investment
Image from Aim Lab

Riot Games has invested in virtual shooting range developer Statespace, accelerating the Los Angeles video game publisher’s efforts to dominate the mobile gaming space.

Read more Show less
https://twitter.com/samsonamore
samsonamore@dot.la

Meet Surf Air Mobility, the Startup Trying To Electrify Air Travel

Samson Amore

Samson Amore is a reporter for dot.LA. He previously covered technology and entertainment for TheWrap and reported on the SoCal startup scene for the Los Angeles Business Journal. Samson is also a proud member of the Transgender Journalists Association. Send tips or pitches to samsonamore@dot.la and find him on Twitter at @Samsonamore. Pronouns: he/him

Meet Surf Air Mobility, the Startup Trying To Electrify Air Travel
Courtesy of Surf Air Mobility

The airline industry is a notoriously terrible polluter, with large carriers struggling to find ways to limit the more than 915 million tons of carbon emissions produced by their industry each year.

Read more Show less
https://twitter.com/samsonamore
samsonamore@dot.la

Ranavat’s Founder on How Pregnancy and Ayurveda Inspired Her to Start Her Skincare Company

Yasmin Nouri

Yasmin is the host of the "Behind Her Empire" podcast, focused on highlighting self-made women leaders and entrepreneurs and how they tackle their career, money, family and life.

Each episode covers their unique hero's journey and what it really takes to build an empire with key lessons learned along the way. The goal of the series is to empower you to see what's possible & inspire you to create financial freedom in your own life.

Michelle Ranavat
Photo credit: Grey and Elle

On this episode of Behind Her Empire, Michelle Ranavat talks about how pregnancy and traditional ayurvedic remedies inspired her to start her skincare company, and how she grew it without relying on outside funding.

Read more Show less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending